Lima1 Antibody

What is Lima1 and why is it important in research?

Lima1 (LIM domain and actin binding 1), also known as EPLIN (Epithelial Protein Lost In Neoplasm) or SREBP3, is an actin-binding protein critical for cytoskeletal regulation and dynamics. In humans, the canonical protein has 759 amino acid residues and a mass of 85.2 kDa, with subcellular localization in cell membranes and cytoplasm . Lima1 is significant in research because it plays crucial roles in:

• Actin cytoskeleton regulation

• Membrane stability and blebbing suppression

• Cell adhesion through cadherin-catenin complex interactions

• Tumor suppression in multiple cancer types

• Pluripotency maintenance in stem cells

• Cellular metabolism and mitochondrial function

• Cholesterol absorption in the intestine

What are the optimal fixation and permeabilization conditions for Lima1 immunostaining?

For optimal Lima1 immunostaining:

• Fixation: 4% paraformaldehyde for 10-15 minutes at room temperature is standard for cultured cells. For tissue sections, buffered formalin fixation followed by paraffin embedding is effective.

• Permeabilization: 0.1-0.2% Triton X-100 for 5-10 minutes is suitable for most cell types.

• Epitope retrieval: Heat-mediated antigen retrieval in EDTA buffer (pH 8.0) is recommended for paraffin-embedded tissues .

• Blocking: 10% goat serum for 30-60 minutes helps reduce background.

For flow cytometry applications, fix cells with 4% paraformaldehyde and use specialized permeabilization buffer prior to antibody incubation .

How can I select the most appropriate Lima1 antibody for my specific research application?

Selection criteria should include:

Always verify:

• Species reactivity matching your samples (human, mouse, etc.)

• Recognition of specific domains if studying isoform-specific functions

• Previous validation in literature for your specific application

• Clonality based on need (monoclonals for consistency, polyclonals for stronger signals)

How should I optimize western blot conditions for detecting both Lima1 isoforms simultaneously?

Lima1 exists in two major isoforms (α at 85kDa and β at 110kDa), requiring specific optimization:

• Sample preparation:

  • Include phosphatase inhibitors to preserve phosphorylation states

  • Use RIPA buffer with protease inhibitors for complete extraction

  • Load 20-30μg of total protein per lane

• Gel selection and transfer:

  • Use 7.5-10% SDS-PAGE gels for better separation of both isoforms

  • Transfer at 150mA for 60-90 minutes to ensure complete transfer of larger isoforms

• Antibody selection:

  • Choose antibodies recognizing epitopes common to both isoforms

  • The middle region (AA 161-260) antibodies typically detect both forms

• Signal development:

  • Use enhanced chemiluminescent detection systems

  • Extend exposure times to capture both isoforms if expression levels differ significantly

Include positive control lysates from cell lines known to express both isoforms (HeLa, HepG2, or 293T cells) to validate detection .

What are the primary considerations for spatial localization studies of Lima1 in complex tissues?

When investigating Lima1 localization in tissues:

• Sample preparation:

  • Fresh-frozen tissues preserve epitopes but have poorer morphology

  • FFPE tissues require heat-mediated antigen retrieval in EDTA buffer (pH 8.0)

• Antibody validation:

  • Confirm subcellular localization patterns with multiple antibodies

  • Include positive control tissues (placenta, kidney, pancreas)

  • Use Lima1 knockout tissues as negative controls when available

• Co-localization studies:

  • Pair with cytoskeletal markers (F-actin, α-catenin)

  • Include adherens junction proteins (E-cadherin, β-catenin)

  • Consider nuclear counterstaining to assess relationship to nuclear structures

• Image acquisition:

  • Use confocal microscopy for precise subcellular localization

  • Z-stack imaging to capture membrane-associated distributions

  • Super-resolution techniques for detailed cytoskeletal associations

How can I accurately quantify changes in Lima1 expression across different experimental conditions?

For reliable quantification:

• For protein-level quantification:

  • Western blot: Use housekeeping controls appropriate for your experimental conditions

  • Densitometry: Analyze within linear range of detection

  • Normalize to total protein using stain-free technology or Ponceau S staining

  • Consider both isoforms in your analysis (85kDa and 110kDa bands)

• For tissue/cell imaging quantification:

  • Standardize image acquisition parameters

  • Analyze mean fluorescence intensity across multiple fields

  • Use automated analysis software with consistent thresholding

  • Include cell number or area normalization

• For flow cytometry:

  • Report median fluorescence intensity rather than mean

  • Include isotype controls and unstained samples

  • Consider cell cycle phase in interpretation

• Statistical approaches:

  • Use appropriate tests based on data distribution

  • Account for biological and technical replicates separately

  • Consider power analysis to determine sample size needed for detection of expected changes

How can I investigate the differential roles of Lima1 isoforms in cytoskeletal dynamics?

To study isoform-specific functions:

• Isoform-specific detection:

  • Use antibodies targeting unique regions of α (85kDa) and β (110kDa) isoforms

  • Verify specificity using recombinant proteins expressing single isoforms

• Expression manipulation:

  • Design siRNAs targeting isoform-specific exons

  • Create isoform-specific expression constructs with different tags

  • Use CRISPR/Cas9 to specifically target isoform-encoding exons

• Functional assays:

  • Live-cell imaging with fluorescently tagged isoforms

  • Actin dynamics assays (polymerization, depolymerization, bundling)

  • Membrane blebbing suppression assays

  • Cell migration and invasion assays

  • Co-immunoprecipitation to identify isoform-specific binding partners

• Data analysis approach:

  • Quantify actin filament density, organization, and turnover rates

  • Measure membranous vs. cytoplasmic distribution ratios

  • Assess effects on cell morphology parameters

What are the potential explanations for contradictory findings regarding Lima1's role in cancer progression?

The literature shows contradictory roles of Lima1 in different cancer types. These discrepancies may be explained by:

How can I optimize co-immunoprecipitation protocols to investigate Lima1's protein-protein interactions?

For effective Lima1 co-immunoprecipitation:

• Lysis conditions:

  • Use gentle lysis buffers (150-300mM NaCl, 1% NP-40 or 0.5% Triton X-100)

  • Include phosphatase inhibitors to preserve interaction states

  • Lyse cells at 4°C to maintain protein complexes

• Antibody selection:

  • Choose antibodies validated for immunoprecipitation

  • Consider epitope location to avoid blocking interaction domains

  • Use control IgG matched to host species of primary antibody

• Complex capture:

  • Pre-clear lysates with protein A/G beads

  • Use crosslinkers for transient interactions

  • Optimize antibody-to-lysate ratios

  • Consider native IP vs. denaturing conditions based on interaction type

• Verification strategies:

  • Reciprocal IP with antibodies against predicted interaction partners

  • Include positive controls (known interactions like Lima1-actin or Lima1-α-catenin)

  • Use proximity ligation assays to verify interactions in intact cells

  • Combine with mass spectrometry for unbiased interaction discovery

What strategies can address non-specific binding when using Lima1 antibodies in high-background tissues?

For high-background tissues:

• Antibody optimization:

  • Titrate antibody concentration to minimize background

  • Test multiple antibodies recognizing different epitopes

  • Consider monoclonal antibodies for higher specificity

• Blocking improvements:

  • Extended blocking (2+ hours) with 5-10% normal serum

  • Add 0.1-0.3% Triton X-100 to blocking solution

  • Include 1-5% BSA to reduce hydrophobic interactions

  • Consider specialized blocking reagents containing immunoglobulins

• Protocol modifications:

  • Increase wash duration and number of washes

  • Add 0.05-0.1% Tween-20 to wash buffers

  • Perform antigen retrieval optimization

  • Try fluorescence detection instead of enzymatic for cleaner background

• Controls and validation:

  • Include absorption controls (pre-incubating antibody with immunizing peptide)

  • Use Lima1 knockout/knockdown tissues as negative controls

  • Validate with multiple detection methods (IF, IHC, WB)

  • Consider competing off non-specific binding with peptides containing non-specific epitopes

How does Lima1 contribute to pluripotency maintenance, and what experimental approaches can investigate this function?

Lima1 has been identified as a key effector in pluripotency:

• Established mechanisms:

  • Lima1 expression is controlled by the naïve pluripotency circuit

  • It suppresses membrane blebbing in embryonic stem cells

  • It regulates mitochondrial energetics

  • It enables incorporation of pluripotent stem cells into pre-implantation embryos

• Experimental approaches:

  • Generate Lima1 knockout/knockdown in embryonic stem cells

  • Perform live imaging to monitor membrane dynamics

  • Assess mitochondrial function (membrane potential, respiration, ATP production)

  • Analyze naïve vs. primed pluripotency marker expression

  • Test embryoid body formation and differentiation potential

  • Perform chimera formation assays

• Advanced techniques:

  • ChIP-seq to identify transcription factor binding at the Lima1 locus

  • Single-cell transcriptomics during differentiation

  • CRISPR screens to identify genetic interactions

  • Metabolomic profiling to characterize Lima1's impact on stem cell metabolism

How should I approach Lima1 detection in specialized cell types with low abundance expression?

For challenging samples:

• Sample enrichment strategies:

  • Use subcellular fractionation to concentrate membrane/cytoskeletal fractions

  • Employ immunoprecipitation before western blotting

  • Consider tyramide signal amplification for immunostaining

• Detection optimization:

  • Use high-sensitivity ECL substrates for western blots

  • Employ signal enhancement systems (polymer-HRP, biotinyl tyramide)

  • Consider RNAscope for detecting low abundance mRNA

  • Increase primary antibody incubation time (overnight at 4°C)

• Specialized protocols:

  • For flow cytometry: increase cell numbers and optimize fixation/permeabilization

  • For IF/IHC: use fluorescent secondary antibodies with higher quantum yield

  • For western blot: load higher protein amounts and use gradient gels

• Validation approaches:

  • Verify with recombinant protein standards

  • Include positive control lysates from high-expressing tissues

  • Use mRNA detection methods to corroborate protein findings

What methodological considerations are important when studying Lima1's role in cholesterol metabolism?

Lima1 has been identified as a key protein in intestinal cholesterol absorption . When investigating this function:

• Experimental models:

  • Use intestinal epithelial cell lines (Caco-2, IEC-6)

  • Consider polarized cell systems to distinguish apical vs. basolateral effects

  • Use Lima1-deficient mice to assess in vivo cholesterol absorption

  • Employ intestinal organoids for more physiologically relevant models

• Functional assays:

  • Measure cholesterol uptake using radiolabeled or fluorescent cholesterol

  • Assess intestinal cholesterol absorption with fecal dual-isotope ratio methods

  • Analyze plasma lipid profiles (LDL-C, HDL-C, total cholesterol)

  • Examine NPC1L1-Lima1-Myosin Vb complex formation

• Localization studies:

  • Focus on brush border membrane localization

  • Use super-resolution microscopy to examine co-localization with NPC1L1

  • Perform subcellular fractionation to isolate membrane microdomains

• Genetic approaches:

  • Analyze human variants (like the frameshift mutation found in Kazakh ethnicity)

  • Create domain-specific mutants to identify regions critical for cholesterol transport

  • Use CRISPR/Cas9 to generate specific mutations corresponding to human variants

What are the key validation steps needed to confirm antibody specificity for Lima1 detection?

To ensure antibody specificity:

• Basic validation:

  • Western blot showing bands at expected molecular weights (85kDa and 110kDa)

  • Reactivity pattern matching known tissue expression profile

  • Subcellular localization consistent with known distribution

• Advanced validation:

  • Testing in Lima1 knockout/knockdown systems

  • Peptide competition assays

  • Reactivity with recombinant protein

  • Concordance of results between antibodies recognizing different epitopes

  • Correlation between protein and mRNA expression patterns

• Application-specific validation:

  • For WB: full blot images showing specificity

  • For IHC/IF: testing on tissues with known expression patterns

  • For flow cytometry: appropriate controls (isotype, secondary-only, unstained)

  • For IP: validation of precipitated protein by mass spectrometry

• Documentation requirements:

  • Record lot numbers and validate each new lot

  • Document all validation experiments

  • Maintain detailed protocols and optimization parameters

How can I resolve discrepancies between Lima1 mRNA and protein expression levels in my experimental system?

When facing mRNA-protein level discrepancies:

• Technical considerations:

  • Verify primers detect all relevant isoforms for qPCR

  • Ensure antibodies recognize all protein isoforms

  • Check for cross-reactivity with related proteins

  • Evaluate detection sensitivity of both methods

• Biological mechanisms:

  • Post-transcriptional regulation (miRNAs, RNA-binding proteins)

  • Post-translational modifications affecting antibody recognition

  • Protein stability and turnover rates

  • Subcellular compartmentalization affecting extraction efficiency

• Investigative approaches:

  • Measure protein half-life with cycloheximide chase

  • Assess proteasomal degradation with inhibitors

  • Examine miRNA targeting of Lima1 transcripts

  • Analyze polysome profiling to assess translation efficiency

• Analytical strategies:

  • Compare multiple time points to detect temporal differences

  • Analyze subcellular fractions separately

  • Consider single-cell analysis to detect population heterogeneity

  • Use absolute quantification methods when possible

What controls should be included when studying Lima1's role in tumor progression models?

For rigorous cancer research with Lima1:

• Expression controls:

  • Multiple normal tissues for baseline expression

  • Gradient of tumor stages/grades to assess progression patterns

  • Multiple cancer cell lines with known Lima1 status

  • Paired normal-tumor samples from the same patients

• Functional controls:

  • Lima1 overexpression and knockdown/knockout models

  • Rescue experiments with wild-type and mutant constructs

  • Domain deletion mutants to identify functional regions

  • Isoform-specific manipulations

• Technical controls:

  • Multiple antibodies targeting different epitopes

  • mRNA and protein detection methods in parallel

  • Multiple experimental models (2D culture, 3D models, in vivo)

  • Time-course experiments to capture dynamic changes

• Outcome measures:

  • Cell proliferation, migration, and invasion assays

  • Tumor growth in xenograft models

  • Metastatic potential assessment

  • Patient survival correlation analysis